Published in J Clin Microbiol on February 01, 2000
Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev (2011) 2.22
Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med (2006) 1.57
Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol (2001) 1.45
Comparison of quantitative competitive PCR with LightCycler-based PCR for measuring Epstein-Barr virus DNA load in clinical specimens. J Clin Microbiol (2002) 1.19
Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood. J Clin Microbiol (2007) 1.12
Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol (2002) 1.08
Predictive value of quantitative PCR-based viral burden analysis for eight human herpesviruses in pediatric solid organ transplant patients. J Mol Diagn (2000) 1.06
Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol (2001) 1.05
Development of real-time PCR assays for the quantitative detection of Epstein-Barr virus and cytomegalovirus, comparison of TaqMan probes, and molecular beacons. J Mol Diagn (2003) 1.00
The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood (2016) 0.99
Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant (2012) 0.92
Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation. J Clin Microbiol (2008) 0.91
Monitoring and managing viral infections in pediatric renal transplant recipients. Pediatr Nephrol (2011) 0.86
Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia. Oncotarget (2016) 0.84
Investigation of epstein-barr virus as a potential cause of B-cell non-Hodgkin lymphoma in a prospective cohort. Cancer Epidemiol Biomarkers Prev (2013) 0.83
Early impairment of CD8+ T cells immune response against Epstein-Barr virus (EBV) antigens associated with high level of circulating mononuclear EBV DNA load in HIV infection. J Clin Immunol (2004) 0.81
Is there diagnostic value in detection of immunoglobulin g antibodies to the epstein-barr virus early antigen? Biores Open Access (2012) 0.80
Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients. Virol J (2011) 0.79
Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient. Med Microbiol Immunol (2010) 0.77
Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma. BMC Cancer (2005) 0.75
Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study. PLoS One (2017) 0.75
Long-term follow-up of Epstein-Barr virus viremia in pediatric recipients of renal transplants. Pediatr Nephrol (2004) 0.75
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 4.07
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med (1990) 3.88
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Infections in solid-organ transplant recipients. Clin Microbiol Rev (1997) 2.86
Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med (1982) 2.44
Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol (1994) 2.15
Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol (1997) 2.05
Lymphoproliferative disorders in cardiac transplant recipients are multiclonal lymphomas. Lancet (1984) 2.03
Quantification of human cytomegalovirus DNA in peripheral blood polymorphonuclear leukocytes of immunocompromised patients by the polymerase chain reaction. J Virol Methods (1993) 1.75
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood (1995) 1.73
The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation (1988) 1.72
Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood (1988) 1.72
Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol (1989) 1.65
In situ demonstration of Epstein-Barr viral genomes in viral-associated B cell lymphoproliferations. Am J Pathol (1989) 1.60
Detection of Epstein-Barr virus by polymerase chain reaction. J Clin Microbiol (1990) 1.57
Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant (1992) 1.54
The changing pattern of posttransplant malignancies. Transplant Proc (1991) 1.42
Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients. Clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol (1990) 1.31
Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation (1995) 1.28
Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med (1984) 1.22
Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med (1991) 1.18
Post-transplant lymphoproliferative disorders: a morphologic, phenotypic and genotypic spectrum of disease. Histopathology (1992) 1.16
Posttransplantation lymphoproliferative disorders. Am J Clin Pathol (1993) 1.15
Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg (1996) 1.14
Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol (1998) 1.09
Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med (1988) 1.07
A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder. Transplantation (1992) 0.87
Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J Infect Dis (1991) 3.42
Detection and characterization of novel rotavirus strains in the United States. J Clin Microbiol (1998) 2.16
Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol (1994) 2.15
Detection of human cytomegalovirus immediate early antigen in leukocytes as a marker of viremia in immunocompromised patients. J Med Virol (1989) 2.11
Isolation and characterization of two distinct human rotavirus strains with G6 specificity. J Clin Microbiol (1992) 2.03
Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant (2015) 2.03
Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J Infect Dis (1992) 1.81
Slow sodium channel inactivation in mammalian muscle: a possible role in regulating excitability. Muscle Nerve (1988) 1.80
Quantification of human cytomegalovirus DNA in peripheral blood polymorphonuclear leukocytes of immunocompromised patients by the polymerase chain reaction. J Virol Methods (1993) 1.75
In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J Gen Virol (2001) 1.74
Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis (2007) 1.73
A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol (1995) 1.71
Comparison between slow sodium channel inactivation in rat slow- and fast-twitch muscle. J Physiol (1987) 1.71
Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler (2008) 1.70
Experience with itraconazole in cryptococcosis and aspergillosis. J Infect (1989) 1.69
Circulating endothelial giant cells permissive for human cytomegalovirus (HCMV) are detected in disseminated HCMV infections with organ involvement. J Clin Invest (1993) 1.64
A strategy for validation of bioanalytical methods. J Pharm Biomed Anal (1996) 1.64
Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant (2007) 1.61
Rapid serotyping of human rotavirus strains by solid-phase immune electron microscopy. J Clin Microbiol (1984) 1.60
Correlation between immunofluorescent detection of human cytomegalovirus immediate early antigens in polymorphonuclear leukocytes and viremia. J Infect Dis (1989) 1.59
Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol (2007) 1.57
Nuclear expression of the lower matrix protein of human cytomegalovirus in peripheral blood leukocytes of immunocompromised viraemic patients. J Gen Virol (1992) 1.53
Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis (1998) 1.51
Clinical severity and molecular typing of human rhinovirus C strains during a fall outbreak affecting hospitalized patients. J Clin Virol (2009) 1.47
Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis (1989) 1.47
Serotyping of cell culture-adapted subgroup 2 human rotavirus strains by neutralization. Infect Immun (1984) 1.46
Postinfectious inflammatory disorders: subgroups based on prospective follow-up. Neurology (2005) 1.43
Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group. Antimicrob Agents Chemother (1994) 1.41
In vitro generation of human cytomegalovirus pp65 antigenemia, viremia, and leukoDNAemia. J Clin Invest (1998) 1.39
Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant (2007) 1.39
Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antiviral Res (1992) 1.38
Isolation in Europe of 69 M-like (serotype 8) human rotavirus strains with either subgroup I or II specificity and a long RNA electropherotype. Arch Virol (1990) 1.37
Development and clinical significance of a diagnostic assay based on the polymerase chain reaction for detection of human cytomegalovirus DNA in blood samples from immunocompromised patients. J Clin Microbiol (1992) 1.36
Immunoglobulin G to virus-specific early antigens in congenital, primary, and reactivated human cytomegalovirus infections. Infect Immun (1978) 1.34
Immunology of Down syndrome: a review. Am J Med Genet Suppl (1990) 1.30
Distribution of VP4 gene alleles in human rotaviruses by using probes to the hyperdivergent region of the VP4 gene. J Clin Microbiol (1993) 1.30
Gait abnormalities in minimally impaired multiple sclerosis patients. Mult Scler (1999) 1.29
The immunoperoxidase technique for rapid human cytomegalovirus identification. Arch Virol (1976) 1.28
Diagnostic and prognostic value of human cytomegalovirus load and IgM antibody in blood of congenitally infected newborns. J Clin Virol (1999) 1.25
Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation (2000) 1.24
Development and evaluation of a capture ELISA for IgM antibody to the human cytomegalovirus major DNA binding protein. J Virol Methods (1991) 1.23
Polymerase chain reaction for prenatal diagnosis of congenital human cytomegalovirus infection. J Med Virol (1995) 1.21
Tetracycline treatment and sex-ratio distortion: a role for Wolbachia in the moulting of filarial nematodes? Int J Parasitol (2002) 1.21
Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology (2010) 1.21
Characterization of serotypes of human rotavirus strains by solid-phase immune electron microscopy. J Infect Dis (1985) 1.20
Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant (2010) 1.20
Identification of two subtypes of serotype 4 human rotavirus by using VP7-specific neutralizing monoclonal antibodies. J Clin Microbiol (1988) 1.20
A trial of high-dose dexamethasone therapy for chronic idiopathic thrombocytopenic purpura in childhood. J Pediatr (1997) 1.20
Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation (1999) 1.19
Comparison and application of a novel genotyping method, semiautomated primer-specific and mispair extension analysis, and four other genotyping assays for detection of hepatitis C virus mixed-genotype infections. J Clin Microbiol (2000) 1.18
Electropherotype heterogeneity within serotypes of human rotavirus strains circulating in Italy. Brief report. Arch Virol (1987) 1.18
Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation. J Infect Dis (1996) 1.15
An anatomically based protocol for the description of foot segment kinematics during gait. Clin Biomech (Bristol, Avon) (1999) 1.14
Prenatal diagnosis of rubella virus infection by direct detection and semiquantitation of viral RNA in clinical samples by reverse transcription-PCR. J Clin Microbiol (1997) 1.14
Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol (2001) 1.14
Functional regions of the human cytomegalovirus protein pUL97 involved in nuclear localization and phosphorylation of ganciclovir and pUL97 itself. J Gen Virol (1998) 1.13
Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant (2008) 1.13
Prevalence of human rotavirus serotypes in some European countries 1981-1988. Scand J Infect Dis (1990) 1.12
Group- and type-specific serologic response in infants and children with primary rotavirus infections and gastroenteritis caused by a strain of known serotype. J Infect Dis (1990) 1.12
Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J (1984) 1.11
The Cys607-->Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob Agents Chemother (1998) 1.11
Antigenic and biological relationships between human coronavirus OC43 and neonatal calf diarrhoea coronavirus. J Gen Virol (1981) 1.11
Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood (1999) 1.10
Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. J Clin Microbiol (1999) 1.10
Determination of neutralizing antibody and IgG antibody to varicella-zoster virus and of IgG antibody to membrane antigens by the immunoperoxidase technique. J Infect Dis (1977) 1.10
Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation (2000) 1.10
Characterization of unusual G8 rotavirus strains isolated from Egyptian children. Arch Virol (1999) 1.10
Immunoperoxidase technique for detection of antibodies to human cytomegalovirus. J Clin Microbiol (1976) 1.09
Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study. J Neurol Neurosurg Psychiatry (2011) 1.08
Quantitation of herpes simplex virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis by the polymerase chain reaction. Clin Diagn Virol (1997) 1.08
Identification of a new VP4 serotype of human rotaviruses. Virology (1994) 1.07
Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant (2012) 1.07
Electropherotypes, subgroups and serotypes of human rotavirus strains causing gastroenteritis in infants and young children in Palermo, Italy, from 1985 to 1989. Res Virol (1991) 1.07
Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation (2003) 1.06